Prostaglandin analogues and phosphodiesterase inhibitors, either alone or as add-on therapy, are effective treatments for vitiligo repigmentation.

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for ...

Patients with vitiligo may significantly improve the effectiveness of a commonly used light therapy — by nearly twofold— by ...

All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC ... S0140-6736(14)60763-7 2 Consensus on the diagnosis and treatment of vitiligo (2021 version) 3 Kubelis-López DE, Zapata ...

All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued ... class (FIC) and best-in-class (BIC ...

Besides vitiligo, a skin depigmenting disorder that affects 1-2% of the global population, Ahammune is also developing treatments for other dermatological conditions. “Currently, our second ...

In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement ... global first-in-class (FIC) and best-in-class (BIC) innovative products ...

VASI is a valid and reliable tool that is responsive to change and has defined thresholds for meaningful improvement for patients with vitiligo.